Tricitrasol Coupons & Savings Card – Discount Prices from $1.01

Tricitrasol is a concentrated anticoagulant solution containing 46.7% trisodium citrate, primarily used in granulocytapheresis procedures. It is crucial to handle and administer this product correctly to avoid serious health risks.

Dilution Requirement: Tricitrasol must be diluted before use. Direct intravenous infusion of the undiluted solution is strictly prohibited due to the high concentration of trisodium citrate, which can lead to severe complications.

Proper Administration: The product is intended for use in specific medical procedures, such as granulocytapheresis. It should not be used for other anticoagulant purposes without appropriate medical guidance.

Storage and Handling: Store Tricitrasol at room temperature, between 15°C and 30°C (59°F to 86°F). Protect it from freezing and excessive heat. Before use, ensure the solution is clear and the seal is intact. If the solution appears cloudy or the seal is compromised, do not use the product.

Aseptic Technique: Maintain strict aseptic technique during preparation and administration to prevent contamination and infection.

Single-Use Only: Tricitrasol is designed for single-use on a single occasion. Any unused portion should be discarded to prevent potential risks associated with reuse.

Monitoring for Citrate Toxicity: Patients receiving blood products containing citrate anticoagulants should be monitored for signs of citrate toxicity. Symptoms may include tingling sensations around the mouth or extremities, chills, stomach cramps, chest pressure, low blood pressure, and possible heart rhythm disturbances. Individuals with conditions such as hypothermia, impaired liver or kidney function, or low calcium levels may be at higher risk for citrate toxicity.

Recall Notice: In April 2000, the FDA issued a warning regarding Tricitrasol after a patient experienced a fatal cardiac arrest following the direct infusion of the undiluted solution into a hemodialysis catheter. This incident underscores the importance of proper dilution and administration. Healthcare providers are advised to discontinue the use of Tricitrasol in hemodialysis settings and consider alternative anticoagulant solutions.

By adhering to these guidelines, healthcare professionals can minimize the risks associated with Tricitrasol and ensure patient safety during its use.

Tricitrasol, a concentrated sodium citrate solution, is primarily used as an anticoagulant in granulocytapheresis procedures. When combined with a 6% hydroxyethyl starch (HES) solution, it helps prevent blood clotting during these procedures.

While Tricitrasol is effective in its intended use, it's important to be aware of potential interactions and precautions:

• Direct Intravenous Infusion: Tricitrasol is not meant for direct intravenous infusion. Administering it undiluted into the bloodstream can lead to serious complications, including fatal heart rhythm disruptions, seizures, or bleeding due to calcium depletion.

• Citrate Toxicity: Infusion of blood products containing citrate anticoagulants can result in citrate toxicity. Symptoms may start with tingling sensations around the mouth or in the extremities and can progress to chills, stomach cramps, chest pressure, hypotension, and potential cardiac arrhythmias. Individuals who are hypothermic, have impaired liver or kidney function, or have low calcium levels due to underlying conditions are at a higher risk for citrate toxicity.

• Drug Interactions: There are no known adverse reactions when Tricitrasol is added to rouleaux agents.

Given these considerations, it's crucial to use Tricitrasol strictly as directed, ensuring proper dilution and administration protocols are followed to minimize risks.